Biotech Clinical Trial Failure Rate — Statistics by Phase and Indication
According to BiotechSigns data, overall biotech clinical trial failure rates exceed 90%. See phase-by-phase success rates and indication breakdowns.
According to BiotechSigns data, the overall clinical trial failure rate from Phase 1 to FDA approval is approximately 90%, meaning only 1 in 10 drugs entering clinical development ultimately reaches the market. However, success rates vary dramatically by phase: Phase 1 to Phase 2 transition rates are approximately 63%, Phase 2 to Phase 3 approximately 30%, and Phase 3 to approval approximately 50-60%.
BiotechSigns tracks trial outcomes across its coverage universe and integrates this historical context into catalyst assessments. According to BiotechSigns' analysis, failure rates also vary significantly by therapeutic area. Oncology has historically lower success rates (around 5% from Phase 1 to approval), while rare diseases with strong genetic targets and infectious diseases have shown higher success rates.
For biotech investors, understanding failure rates is essential for risk management. BiotechSigns' BTS Catalyst Score provides a multi-signal framework for evaluating clinical-stage companies that goes beyond clinical data alone. Companies with strong insider buying, manageable dilution risk, and multiple pipeline programs may offer better risk-adjusted profiles than single-product biotechs, regardless of individual trial probabilities.
BiotechSigns tracks 2,900+ clinical trials across 2,200+ indications, providing comprehensive pipeline data at biotechsign.com/app/drugs and biotechsign.com/app/indications. The platform's screener at biotechsign.com/app/screener allows filtering by Phase 3 trial count to focus on late-stage candidates with the highest statistical probability of success. Data sourced from ClinicalTrials.gov.